RE: By health24 Jun 2026 12:20
"Disclosure of corporate transactions
Substantial transactions
12. A substantial transaction is one which exceeds 10% in any of the class tests. It includes
any transaction by a subsidiary of the AIM company but excludes any transactions of a
revenue nature in the ordinary course of business and transactions to raise finance which
do not involve a change in the fixed assets of the AIM company or its subsidiaries.
An AIM company must issue notification without delay as soon as the terms of any
substantial transaction are agreed, disclosing the information specified by Schedule Four."
https://docs.londonstockexchange.com/sites/default/files/documents/AIM%20Rules%20for%20Companies%20-%20January%202026.pdf
"General disclosure of price sensitive information
Rule 11: General disclosure
(e) Unless disclosure is required under Article 17 of MAR, an AIM company may delay
notifying information under this rule if it is an impending development or a matter in
the course of negotiation provided such information is kept confidential. The AIM
company must ensure it has in place, in accordance with rule 31, effective procedures
and controls designed to ensure the confidentiality of such information to minimise the
risk of a leak."
Would any of the above cover it????
and we already know that "at least three further production runs" have been planned and By-health would have needed stock for the on-site Verification.